Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose versus three-dose cefazolin prophylaxis for cesarean section infection prevention
IRCT20240731062600N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Apr 2023
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-blind trial of cefazolin in surgical site infection (SSI) (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Infection after cesarean section. Started Apr 2023; status: completed.
02
Drugs
cefazolin
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on IRCT20240731062600N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240731062600N1.